Preclinical Detection and Monitoring of Alzheimer’s Disease Using a Multi‐Disease Diagnostic Platform Employing Autoantibodies as Blood‐based Biomarkers

Evidence for the universal presence of serum autoantibodies and their potential diagnostic utility for detection of Alzheimer’s disease (AD) and other neurodegenerative diseases has been extensively demonstrated by our laboratory. It is well known that AD‐related pathological changes in the brain can begin up to a decade before patients experience telltale symptoms, yet preclinical detection remains an unmet goal. In the present study, we demonstrate the utility of a panel of AD‐related autoantibodies capable of detecting AD at the earliest points along the AD continuum, including preclinical AD, years before the onset of symptoms, and prodromal AD (mild cognitive impairment, MCI).